Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ImmuCell Corp ICCC

Healthcare Biotechnology
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which... see more

Recent & Breaking News (NDAQ:ICCC)

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

GlobeNewswire February 21, 2023

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

GlobeNewswire February 15, 2023

ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022

GlobeNewswire January 9, 2023

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022

GlobeNewswire November 21, 2022

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022

GlobeNewswire November 10, 2022

ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022

GlobeNewswire October 5, 2022

ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference

GlobeNewswire September 14, 2022

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022

GlobeNewswire August 11, 2022

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

GlobeNewswire August 4, 2022

ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®

GlobeNewswire July 27, 2022

ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

GlobeNewswire July 7, 2022

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

GlobeNewswire May 19, 2022

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022

GlobeNewswire May 12, 2022

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022

GlobeNewswire May 10, 2022

UPDATE -- Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

GlobeNewswire May 5, 2022

Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement

GlobeNewswire May 5, 2022

ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022

GlobeNewswire April 11, 2022

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

GlobeNewswire February 22, 2022

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021

GlobeNewswire February 16, 2022

ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021

GlobeNewswire January 5, 2022